Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children

International Journal of Infectious Diseases

Volumn 12, Issue 3, 2008, Pages 270-277

  Abarca, Katia ^a   Ibánez, Isabel ^a   Perret, Cecilia ^a   Vial, Pablo ^a   Zinsou, Jean Antoine ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b SANOFI PASTEUR   (France)

Author keywords

Children; Hepatitis A vaccine; Immunogenicity; Interchangeability; Safety

Indexed keywords

AVAXIM 80U PEDIATRIC; HAVRIX 720; HEPATITIS A VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG SAFETY; GLOMERULONEPHRITIS; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; INJECTION PAIN; MAJOR CLINICAL STUDY; SEROCONVERSION; VACCINATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHILE; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS A VIRUS, HUMAN; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; TREATMENT OUTCOME; VACCINES, INACTIVATED;

EID: 42149105259     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2007.08.006     Document Type: Article

References (33)

1. Forbes A., and Williams R. Increasing age: an important adverse prognostic factor in hepatitis A infection. J R Coll Phys (London) 22 (1988) 237-239
2. Lieberman J.M., and Greenberg D.P. Hepatitis A and B vaccines in children. Adv Pediatr Infect Dis 11 (1996) 333-363
3. Gust I.D. Epidemiological patterns of hepatitis A in different parts of the World. Vaccine 10 Suppl 1 (1992) S56-S58
4. Shapiro C.N., and Margolis H.S. Worldwide epidemiology of hepatitis A virus infection. J Hepatol 18 Suppl 2 (1993) S11-S14
5. Dagan R., Leventhal A., Anis E., Slater P., Ashur Y., and Shouval D. Incidence of hepatitis A in Israel following universal immunization of Toddlers. JAMA 294 (2005) 202-210
6. Averhoff F., Shapiro C.N., Bell B.P., Hyams I., Burd L., Deladisma A., et al. Control of hepatitis A through routine vaccination of children. JAMA 286 (2001) 2968-2973
7. Ministro de Salud y Ambiente, Argentina. Comenzó la vacunación gratuita contra la hepatitis A en todo el país 20/5/2005. Available at: http://www.msal.gov.ar/htm/site/Noticias_plantilla.asp?Id=569 (accessed September 2007).
8. Tanaka J. Hepatitis A shifting epidemiology in Latin America. Vaccine 18 Suppl 1 (2000) S57-S60
9. Tapia-Conyer R., Santos J.I., Cavalcanti A.M., Urdaneta E., Rivera L., Manterola A., et al. Hepatitis A in Latin America: a changing epidemiologic pattern. Am J Trop Med Hyg 61 (1999) 825-829
10. Fix A.D., Martin O.S., Gallicchio L., Vial P.A., and Lagos R. Age-specific prevalence of antibodies to hepatitis A in Santiago, Chile: risk factors and shift in age of infection among children and young adults. J Trop Med Hyg 66 (2002) 628-632
11. Ministerio de Salud, Chile, Departamento de Epidemiología. Situación de las enfermedades de notificación obligatoria: hepatitis A. Boletín Electrónico Mensual de Vigilancia Epidemiológica No. 43. Publicación 16 de Junio Año 2006. Available at: http://epi.minsal.cl/evigant/Numero43/evigia/index.html (accessed September 2007).
12. Ministerio de Salud, Chile, Departamento de Epidemiología. Hepatitis A y hepatitis sin especificación: Situación 2005. Available at: http://epi.minsal.cl/epi/html/bolets/reportes/hepatitisA.htm (accessed September 2007).
13. Innis B.L., Snitbhan R., Kunasol P., Laorakpongse T., Poopatanakool W., Kozik C., et al. Protection against hepatitis A by an inactivated vaccine. JAMA 271 (1994) 1328-1334
14. Werzberger A., Mensch B., Kuter B., Brown L., Lewis J., Sitrin R., et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327 (1992) 453-457
15. Prikazsky V., Olear V., Cernoch A., Safary A., and Andre F.E. Interruption of an outbreak of hepatitis A in two villages by vaccination. J Med Virol 44 (1994) 457-459
16. McMahon B.J., Beller M., Williams J., Schloss M., Tanttila H., and Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med 150 (1996) 733-739
17. Sagliocca L., Amoroso P., Stroffolini T., Adamo B., Tosti M.E., Lettieri G., et al. Efficacy of hepatitis vaccine in prevention of secondary hepatitis A infection: a randomized trial. Lancet 353 (1999) 1136-1138
18. Dagan R., Greenberg D., Goldenberg-Gehtman P., Vidor E., Briantais P., Pinsk V., et al. Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine. Vaccine 17 (1999) 1919-1925
19. López E., Del Carmen Xifró M., Torrado L., De Rosa F., Gómez R., Dumas R., et al. Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. Pediatr Infect Dis J 20 (2000) 48-52
20. Lolekha S., Pratuangtham S., Punpanich W., Bowonkiratikachorn P., Chimabutra K., and Weber F. Immunogenicity and safety of two doses of a paediatric hepatitis A vaccine in Thai children: comparison of three vaccination schedules. J Trop Pediatr 49 (2003) 333-339
21. Vidor E., Dumas R., Porteret V., Bailleux F., and Veitch K. Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data. Eur J Clin Microbiol Infect Dis 23 (2004) 300-309
22. Zuckerman J., Peyron F., Wallon M., Gay F., Delolme H., Briantais P., et al. Comparison of the safety and immunogenicity of two inactivated hepatitis A vaccines. Adv Ther 14 (1997) 116-124
23. Goilav C., Zuckerman J., Lafrenz M., Vidor E., Lauwers S., Ratheau C., et al. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. J Med Virol 46 (1995) 287-292
24. Zuckerman J.N., Kirkpatrick C.T., and Huang M. Immunogenicity and reactogenicity of Avaxim (160AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A. J Travel Med 5 (1998) 18-22
25. Flehmig B., Staedele H., Xueref C., Vidor E., Zuckerman J., and Zuckerman A. Early appearance of neutralizing antibodies after vaccination with an inactivated hepatitis A vaccine. J Infect 35 (1997) 37-40
26. Van Herck K., Beutels P., Van Damme P., Beutels M., Van den Dries J., Briantais P., et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 60 (2000) 1-7
27. Van Damme P., Thoelen S., Cramm M., De Groote K., Safary A., and Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 44 (1994) 446-451
28. D'Argenio P., Adamo B., Cirrincione R., and Gallo G. The role of vaccine in controlling hepatitis A epidemics. Vaccine 21 (2003) 2246-2249
29. Sagliocca L., Amoroso P., Stroffolini T., Adamo B., Tosti M.E., Lettieri G., et al. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomized trial. Lancet 353 (1999) 1136-1139
30. Abarca K., Ibanez I., Flores J., Vial P.A., Safary A., and Potin M. Efficacy of hepatitis A vaccination in children aged 12 to 24 months. Arch Med Res 32 (2001) 468-472
31. Dominguez A., Salleras L., Carmona G., and Batalla J. Effectiveness of a mass hepatitis A vaccination program in preadolescents. Vaccine 21 (2003) 698-701
32. Fiore A.E., Wasley A., and Bell B.P. Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 RR-7 (2006) 1-23
33. Valenzuela M.T., Jacobs R.J., Arteaga O., Navarrete M.S., Meyerhoff A.S., and Innis B.L. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Vaccine 23 (2005) 4110-4119